Low molecular weight heparin treatment decreases MMP-9 plasma activity in patients with abdominal aortic aneurysm.
Large abdominal aortic aneurysms (AAAs) are associated with coagulation abnormalities, which are significantly reduced by low molecular weight heparin (LMWH). Considering anti-inflammatory properties of heparin we verified, whether LMWH influences MMP-2/-9 in AAA patients. The study involved 26 AAA individuals, 10 patients with coagulation abnormalities received LMWH and 16 were a control group. The plasma activity of MMP-2/-9 was measured using zymography. We found that, in addition to the reduction of coagulation abnormalities, LMWH treatment was associated with the decreased MMP-9 but not MMP-2 activity. Therefore, LMWH use could be considered as a valuable pretreatment before an elective aneurysm repair.
Grzela
T
T
Department of Histology and Embryology, Warsaw Medical University, Poland. tgrzela@op.pl
Brawura-Biskupski-Samaha
R
R
Jelenska
M M
MM
Szmidt
J
J
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D017544:Aortic Aneurysm, Abdominal / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000601:surgery; D001777:Blood Coagulation / Q000187:drug effects; D003131:Combined Modality Therapy; D015536:Down-Regulation; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9